title: Conjugated linoleic acid supplementation enhances antihypertensive effect of ramipril in Chinese patients with obesity-related hypertension.
abstract: BACKGROUND
  Conjugated linoleic acid (CLA) refers to a group of positional and geometrical conjugated dienoic isomers of linoleic acid. Our aim was to investigate the effect of 8-week dietary CLA supplementation on blood pressure, concentrations of plasma adiponecin, leptin, and as well as angiotensin-converting enzyme (ACE) activity in obese hypertensive subjects.
  
  
  METHODS
  Eighty obese individuals with stage 1 uncontrolled essential hypertension were randomized in a double-blind, placebo-controlled trial. Participants were randomized to a daily dose of 4.5 g/day CLA (nine 0.5-g capsules; a 50:50 isomer blend of c 9,t 11 and t 10,c 12 CLA) with 37.5 mg/day ramipril (group 1) or placebo with 37.5 mg/day ramipril (group 2) for 8 weeks. Baseline and endpoint systolic BP, diastolic BP, and concentrations of plasma adiponecin, leptin, angiotensinogen, and ACE activity were measured.
  
  
  RESULTS
  Treatment with CLA significantly enhanced the reduction effect of ramipril on systolic BP and diastolic BP (P < 0.05). It also increased plasma adiponectin concentration (P < 0.05) and decreased plasma concentrations of leptin and angiotensinogen (P < 0.05); however, significant change was not observed in ACE activity.
  
  
  CONCLUSIONS
  An 8-week long supplementation of CLA enhanced the effect of ramipril on blood pressure reduction in treated obese hypertensive patients. The antihypertensive effect of CLA might be related to the changed secretion of hypertensive adipocytokines in plasma.
authors.affiliation: Department of Cardiovascular Internal Medicine, Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
authors.forename: Wen-Sheng
authors.initials: WS
authors.lastname: Zhao
authors.forename: Jia-Jie
authors.initials: JJ
authors.lastname: Zhai
authors.forename: Yi-Hui
authors.initials: YH
authors.lastname: Wang
authors.forename: Pa-Sha
authors.initials: PS
authors.lastname: Xie
authors.forename: Xiao-Jing
authors.initials: XJ
authors.lastname: Yin
authors.forename: Long-Xue
authors.initials: LX
authors.lastname: Li
authors.forename: Kang-Lin
authors.initials: KL
authors.lastname: Cheng
mesh_terms: D052242:Adiponectin / Q000097:blood; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000808:Angiotensinogen / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects* / Q000502:physiology; D019587:Dietary Supplements; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004357:Drug Synergism; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D020738:Leptin / Q000097:blood; D044243:Linoleic Acids, Conjugated / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000150:complications* / Q000453:epidemiology; D017257:Ramipril / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D052242:Adiponectin; D000806:Angiotensin-Converting Enzyme Inhibitors; D020738:Leptin; D044243:Linoleic Acids, Conjugated; D000808:Angiotensinogen; D017257:Ramipril